Peptides for diagnostic and research tools, ranked by human evidence

Peptides used mainly as imaging tracers or laboratory tools rather than treatments; “evidence” here means research use, not clinical benefit. They are ranked by an evidence score that weighs the grade of the evidence, the human trials counted in PubMed, and regulatory status — shown in the columns so any rank can be checked. A high score means a peptide is well studied and often approved for something, not that it is right, safe or legal for this goal. Nothing here is medical advice, and Grey Peptides sells nothing and links to no vendor. See all goals or the plainer browse by goal map.

Evidence grade

Regulatory status

Search name

Has a human trial on this page

91 peptides · sorted by evidence score (click a column to re-sort)

Peptide	Grade	Human studies	RCTs	Max trial phase	Regulatory	Dose	Score
Bleomycin	High	11,840	593	Phase 4	FDA approved	intravenous, intramuscular or subcutaneous →	100
Dactinomycin	High	6,715	144	Phase 4	FDA approved	intravenous →	100
Lutetium-177 DOTATATE	High	2,857	56	Phase 4	FDA approved	intravenous infusion →	100
Gozetotide	High	1,665	33	Phase 3	FDA approved	intravenous →	100
Carfilzomib	High	1,392	72	Phase 4	FDA approved	intravenous →	100
Vipivotide Tetraxetan	High	1,001	33	Phase 4	FDA approved	intravenous →	100
Technetium Tc 99m mertiatide	High	967	4	—	FDA approved	intravenous →	100
Romidepsin	High	784	7	Phase 3	FDA approved	intravenous →	100
Indium In 111 pentetreotide	High	693	3	Phase 4	FDA approved	—	100
Piflufolastat F 18	High	322	4	Phase 4	FDA approved	intravenous →	100
Edotreotide	High	736	4	Phase 3	FDA approved	intravenous →	90
Gallium Ga 68 dotatate	High	482	2	Phase 4	FDA approved	—	90
Tertomotide	High	58	5	Phase 3	Approved abroad	injection (route not stated in the trial abstract) →	90
Melphalan Flufenamide	High	56	3	Phase 3	Approved abroad	intravenous →	90
Copper Cu 64 dotatate	High	30	0	Phase 4	FDA approved	—	90
Nelipepimut-S	High	11	5	Phase 3	In trials	intradermal →	90
Flotufolastat F 18	High	10	0	Phase 2	FDA approved	intravenous →	90
Lucinactant	High	45	6	Phase 3	Discontinued	intratracheal →	85
Recombinant Human Endostatin	Medium	390	43	Phase 4	Approved abroad	intravenous →	70
DOTANOC	Medium	362	2	Phase 4	In trials	intravenous →	70
PSMA-1007	Medium	317	6	Phase 3	Approved abroad	intravenous →	70
Cilengitide	Medium	287	17	Phase 3	In trials	—	70
Pentixafor	Medium	259	1	Phase 3	In trials	intravenous →	70
Zadavotide Guraxetan	Medium	172	3	Phase 3	In trials	intravenous →	70
RM2	Medium	155	6	Phase 3	In trials	intravenous →	70
Plitidepsin	Medium	121	6	Phase 3	Approved abroad	intravenous →	70
Lancovutide	Medium	60	3	Phase 2	Approved abroad	inhaled →	70
Tecemotide	Medium	41	9	Phase 3	In trials	—	70
Brimapitide	Medium	27	4	Phase 3	Approved abroad	intratympanic →	70
Fexapotide	Medium	26	2	Phase 3	In trials	—	70
Lusupultide	Medium	23	5	—	Approved abroad	intratracheal →	70
Disomotide	Medium	19	1	—	Approved abroad	subcutaneous →	70
Alfatide II	Medium	15	1	Phase 4	In trials	intravenous →	70
Maraciclatide	Medium	14	3	Phase 2	In trials	intravenous →	70
Satoreotide Trizoxetan	Medium	11	1	Phase 2	In trials	intravenous →	70
Trofolastat	Medium	10	1	—	In trials	intravenous →	70
DOTA-LM3	Medium	8	3	Phase 2	In trials	intravenous →	70
Elpamotide	Medium	8	1	—	Approved abroad	subcutaneous →	70
Galinpepimut-S	Medium	4	1	Phase 3	In trials	—	70
Depreotide	Medium	90	1	—	Discontinued	—	65
Technetium Tc 99m Apcitide	Medium	41	4	—	Discontinued	intravenous →	65
Emodepside	Medium	39	23	Phase 3	Veterinary	oral →	65
Technetium Tc 99m Etarfolatide	Medium	17	2	Phase 2	Discontinued	intravenous →	65
Certepetide	Medium	301	0	Phase 2	In trials	intravenous →	60
HYNIC-TOC	Medium	132	0	Phase 2	Approved abroad	intravenous →	60
FAP-2286	Medium	61	0	Phase 2	In trials	intravenous →	60
Tesofensine	Medium	48	11	Phase 2	In trials	oral →	60
3PRGD2	Medium	40	0	—	In trials	intravenous →	60
Ubiquicidin 29-41	Medium	39	0	—	In trials	intravenous →	60
Trivehexin	Medium	31	0	—	In trials	intravenous →	60
AlF-NOTA-octreotide	Medium	25	0	Phase 3	In trials	intravenous →	60
NeoB	Medium	22	0	Phase 2	In trials	intravenous →	60
FPPRGD2	Medium	18	0	Phase 2	In trials	intravenous →	60
Balixafortide	Medium	13	0	Phase 3	In trials	—	60
Satoreotide Tetraxetan	Medium	13	0	Phase 2	In trials	intravenous →	60
Fluciclatide	Medium	12	0	Phase 2	In trials	intravenous →	60
Tozuleristide	Medium	11	0	Phase 3	In trials	intravenous →	60
DOTA-EB-TATE	Medium	9	0	Phase 2	In trials	intravenous →	60
NODAGA-exendin-4	Medium	9	0	Phase 2	In trials	intravenous →	60
CP04	Medium	8	0	Phase 3	In trials	intravenous →	60
DOTA-MGS5	Medium	8	0	Phase 2	In trials	intravenous →	60
Zelenectide Pevedotin	Medium	8	0	Phase 2	In trials	intravenous →	60
SARTATE	Medium	5	0	Phase 2	In trials	—	60
DOTAMTATE	Medium	4	0	Phase 2	In trials	intravenous →	60
SAR-bisPSMA	Medium	1	0	Phase 3	In trials	—	60
Bioactive Food Peptides	Medium	176	8	Phase 4	Supplement	—	55
Zoptarelin Doxorubicin	Medium	58	0	Phase 3	Discontinued	—	55
ACE-031	Medium	29	2	Phase 2	Discontinued	subcutaneous →	55
Balenine	Medium	14	0	—	Research only	oral →	55
Pentixather	Medium	35	0	Phase 2	In trials	intravenous →	50
Galacto-RGD	Medium	32	0	—	In trials	intravenous →	50
SiTATE	Medium	27	0	—	In trials	intravenous →	50
PSMA I&S	Medium	3	0	Phase 2	In trials	intravenous →	50
VMT-α-NET	Medium	3	0	Phase 2	In trials	intravenous →	50
Lunasin	Low	85	1	Phase 2	Research only	—	45
Katacalcin	Medium	68	0	Phase 4	Research only	—	45
Cyclo(His-Pro)	Low	56	1	Phase 2	Research only	intravenous →	45
Ruxotemitide	Low	39	0	Phase 2	In trials	intratumoral →	40
MGF	Low	9,581	316	Phase 4	Research only	—	35
Follistatin-344	Low	1,733	68	Phase 1	Preclinical	—	35
Prolyl-Hydroxyproline	Low	166	8	—	Research only	—	35
Dermorphin	Low	61	1	—	Research only	—	35
IGF-1 LR3	Low	41	1	—	Research only	—	35
PEG-MGF	Low	5	1	Phase 2	Research only	—	35
Nendratareotide Uzatansine	Low	5	0	—	Approved abroad	—	30
Corticotropin-like intermediate peptide (CLIP)	Low	40	0	—	Research only	—	25
PNC-27	Low	18	0	—	Preclinical	—	25
Follistatin-315	Low	15	0	—	Preclinical	—	25
IGF-1 DES(1-3)	Low	14	0	—	Research only	—	25
Cyclic Glycine-Proline	Low	13	0	—	Research only	—	25
Adipotide	Low	8	0	—	Preclinical	—	25

Other goals: Weight loss and metabolism · Healing, injury and recovery · Skin and hair · Focus, mood and the brain · Growth hormone and body composition · Heart and circulation · Sexual and reproductive health · Longevity and cell health · Immune defence and infection · In development

How the evidence score works

Evidence score (0-100), a transparent ranking aid, not a verdict. grade: high=60, medium=40, low=20, ungraded=0. Human trial: an on-site read-and-cited randomized or clinical trial = +15, else any PubMed human-indexed record = +5, else 0. RCT literature: PubMed lists >=1 randomized controlled trial = +10. Regulatory: FDA-approved = +15, in trials / approved-abroad / in development = +5, else 0. Every component is stored on each record so the number can be re-derived; volume and grade are shown together so neither misleads.

“Human studies” and “RCTs” are PubMed record counts for the peptide (read 2026-11-07 from the counts behind the Evidence Explorer); a count is how much research exists and of what kind, never proof a peptide works. “Grade” is our editorial reading of the evidence — see how we grade evidence. The “Dose” column links to the entry for each peptide that carries a dose from a regulator’s label or a published human study — where the amount is shown with its source; the amount is never reprinted here without that source, and many research peptides have no human dose, shown as —. Of 660 peptides, 607 have at least one human-indexed PubMed record, 324 cite a human trial on their page, 124 are FDA-approved, and 271 carry a sourced dose.